Papillomaviruses in human cancers.

Papillomaviruses have proved to be the most complex group of human pathogenic viruses. Eighty-five genotypes have been fully characterized; approximately 120 additional isolates represent only partially characterized putative novel genotypes. Specific types, most notably human papillomavirus (HPV) types 16, 18, and a few others, have been shown to cause the majority of cervical cancers and their high-grade precursor lesions. The viral oncogenes E6 and E7 are required for the initiation and maintenance of the malignant phenotype in HPV-positive cancers. Proteins coded by these genes are multifunctional and interfere with important cell cycle regulatory proteins. Expression of viral oncogenes is tightly controlled in nondifferentiated keratinocytes by at least two signaling cascades, one operative at the functional level, the other at the transcriptional level. The latter has been partially characterized. Papillomaviruses are also suspected of playing a role in a subset of oropharyngeal cancers, in squamous cell cancers of the skin, and possibly also in esophageal cancers. Clinical trials are being conducted to test the preventive and therapeutic efficacy of HPV vaccines, directed particularly against HPV 16 and 18. If proven to be effective, their global application should have a measurable effect on the worldwide incidence of cancer.

[1]  E. de Villiers,et al.  The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence , 1999, The EMBO journal.

[2]  F. Rösl,et al.  Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex , 1999, Oncogene.

[3]  E. de Villiers,et al.  Papillomavirus in esophageal papillomas and carcinomas , 1999, International journal of cancer.

[4]  E. de Villiers,et al.  Prevailing papillomavirus types in non‐melanoma carcinomas of the skin in renal allograft recipients , 1997, International journal of cancer.

[5]  K. Münger,et al.  The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. , 1997, Genes & development.

[6]  B. Stillman,et al.  Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. , 1997, Genes & development.

[7]  F. Rösl,et al.  Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription , 1997, Journal of virology.

[8]  E. de Villiers,et al.  Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. , 1996, Journal of the National Cancer Institute.

[9]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.

[11]  M. Scheffner,et al.  A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Smits,et al.  Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients , 1995, Journal of clinical microbiology.

[13]  M. von Knebel Doeberitz,et al.  Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions , 1994, Journal of virology.

[14]  H. Hausen Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix , 1994, The Lancet.

[15]  F. Rösl,et al.  Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids , 1994, Journal of virology.

[16]  T. Tlsty,et al.  Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. , 1994, Genes & development.

[17]  S Wacholder,et al.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. , 1993, Journal of the National Cancer Institute.

[18]  M. von Knebel Doeberitz,et al.  Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV e6‐e7 anti‐sense RNA , 1992, International journal of cancer.

[19]  S. Syrjänen,et al.  Human papillomavirus involvement in esophageal precancerous lesions and squamous cell carcinomas as evidenced by microscopy and different DNA techniques. , 1992, Scandinavian journal of gastroenterology.

[20]  H. zur Hausen,et al.  Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. , 1992, Virology.

[21]  F. X. Bosch,et al.  Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines , 1991, Journal of virology.

[22]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[23]  Harald,et al.  Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells , 1990, Journal of virology.

[24]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[25]  G. Orth,et al.  Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Jabłońska,et al.  Zur Kenntnis der Epidermodysplasia verruciformis Lewandowsky-Lutz , 1957 .

[27]  G. Hilt Le fer sérique du sang variqueux en rapport avec la dermite ocre de Favre et Chaix , 1955 .

[28]  J. R. E. Silva L’innervation de la peau ne paraît jouer aucun rôle dans le mécanisme de la sensibilisation de la peau au di-nitro-chlorobenzène , 1955 .

[29]  P. Rous,et al.  THE EFFECT OF CHEMICAL CARCINOGENS ON VIRUS-INDUCED RABBIT PAPILLOMAS , 1944, The Journal of experimental medicine.

[30]  M. Tommasino Papillomaviruses in Human Cancer , 1997, Springer US.

[31]  E. Villiers Human Pathogenic Papillomavirus Types: An Update , 1994 .

[32]  J. McDougall Immortalization and transformation of human cells by human papillomavirus. , 1994, Current topics in microbiology and immunology.

[33]  T. Shenk,et al.  Genetic analysis of adenoviruses. , 1984, Current topics in microbiology and immunology.

[34]  W. Lutz A propos de l’Epidermodysplasie verruciforme , 1946 .